Antibody Drug Conjugates (ADCs) – An Emerging Treatment Platform in Lung Cancer

In this TOGA Podcast the speakers discuss Antibody Drug Conjugates (ADCs) – An Emerging Treatment Platform in Lung Cancer. The discussion explores the different molecules and mechanisms of drugs currently available, trial results and the subsequent place of ADCs in the Lung Cancer. Furthermore, our guests expand upon the management of patients receiving these drugs. A/Prof Melissa Moore, Medical Oncologist at St Vincent’s Hospital Melbourne, is joined in this conversation by fellow medical oncologists A/Prof Tom John from Peter MacCallum Cancer Centre in Melbourne and A/Prof Adnan Nagrial from Westmead Hospital in Sydney. Support TOGA Thank you for listening to Conversations in Lung Cancer Research. If you enjoyed this episode, please rate and review us on Apple Podcasts or Spotify. --------------- Connect with TOGA Attend an Event: https://thoraciconcology.org.au/events/ Become a Member: Join the TOGA community at https://thoraciconcology.org.au/membership/ Donate: Support our research and treatment initiatives at https://thoraciconcology.org.au/support-us/donate/ Follow Us LinkedIn: https://www.linkedin.com/company/thoracic-oncology-group-of-australasia/ X (Twitter): https://x.com/TOGAANZ Instagram: https://www.instagram.com/togaanz/ YouTube:  https://www.youtube.com/@Thoracic_Oncology --------------- Acknowledgement of Country The Thoracic Oncology Group of Australasia Limited acknowledges Traditional Owners of Country throughout Australia and recognises the continuing connection to lands, waters and communities. We pay our respect to Aboriginal and Torres Strait cultures; and to Elders past and present.